Citigroup Maintains Neutral on Hologic, Raises Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Patrick Donnelly has maintained a Neutral rating on Hologic (NASDAQ:HOLX) and increased the price target from $80 to $95.

April 03, 2024 | 2:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup has maintained a Neutral rating on Hologic, but raised the price target from $80 to $95.
The increase in price target by Citigroup suggests a positive outlook on Hologic's stock value in the short term, despite maintaining a Neutral rating. This adjustment could lead to increased investor interest and potentially a rise in stock price as the new target suggests an upside.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90